GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » ROE %

I-MAB (IMAB) ROE % : -6.31% (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. I-MAB's annualized net income for the quarter that ended in Mar. 2025 was $-12.60 Mil. I-MAB's average Total Stockholders Equity over the quarter that ended in Mar. 2025 was $199.75 Mil. Therefore, I-MAB's annualized ROE % for the quarter that ended in Mar. 2025 was -6.31%.

The historical rank and industry rank for I-MAB's ROE % or its related term are showing as below:

IMAB' s ROE % Range Over the Past 10 Years
Min: -65.26   Med: -46.4   Max: 25.27
Current: -3.55

During the past 8 years, I-MAB's highest ROE % was 25.27%. The lowest was -65.26%. And the median was -46.40%.

IMAB's ROE % is ranked better than
75.54% of 1308 companies
in the Biotechnology industry
Industry Median: -39.48 vs IMAB: -3.55

I-MAB ROE % Historical Data

The historical data trend for I-MAB's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB ROE % Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE %
Get a 7-Day Free Trial 25.27 -46.40 -65.26 -62.54 -10.02

I-MAB Quarterly Data
Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.91 42.47 -36.07 -17.30 -6.31

Competitive Comparison of I-MAB's ROE %

For the Biotechnology subindustry, I-MAB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


I-MAB's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's ROE % distribution charts can be found below:

* The bar in red indicates where I-MAB's ROE % falls into.


;
;

I-MAB ROE % Calculation

I-MAB's annualized ROE % for the fiscal year that ended in Dec. 2024 is calculated as

ROE %=Net Income (A: Dec. 2024 )/( (Total Stockholders Equity (A: Dec. 2023 )+Total Stockholders Equity (A: Dec. 2024 ))/ count )
=-22.23/( (242.584+201.16)/ 2 )
=-22.23/221.872
=-10.02 %

I-MAB's annualized ROE % for the quarter that ended in Mar. 2025 is calculated as

ROE %=Net Income (Q: Mar. 2025 )/( (Total Stockholders Equity (Q: Dec. 2024 )+Total Stockholders Equity (Q: Mar. 2025 ))/ count )
=-12.6/( (201.16+198.341)/ 2 )
=-12.6/199.7505
=-6.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2025) net income data. ROE % is displayed in the 30-year financial page.


I-MAB  (NAS:IMAB) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2025 )
=Net Income/Total Stockholders Equity
=-12.6/199.7505
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-12.6 / 0)*(0 / 210.8105)*(210.8105 / 199.7505)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.0554
=ROA %*Equity Multiplier
=N/A %*1.0554
=-6.31 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2025 )
=Net Income/Total Stockholders Equity
=-12.6/199.7505
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-12.6 / -12.6) * (-12.6 / -21.064) * (-21.064 / 0) * (0 / 210.8105) * (210.8105 / 199.7505)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.5982 * N/A % * 0 * 1.0554
=-6.31 %

Note: The net income data used here is four times the quarterly (Mar. 2025) net income data. The Revenue data used here is four times the quarterly (Mar. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


I-MAB ROE % Related Terms

Thank you for viewing the detailed overview of I-MAB's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


I-MAB Business Description

Traded in Other Exchanges
Address
2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).